Abbott’s medical device sales hit by China curbs, supply-chain issues
The multinational healthcare giant recorded overall medical device sales of $3.75 billion, missing analysts’ average estimate of $3.84 billion.
If you are not happy with the results below please do another search
The multinational healthcare giant recorded overall medical device sales of $3.75 billion, missing analysts’ average estimate of $3.84 billion.
A group of 25 senators, led by Sen. Elizabeth Warren (D-MA), requested that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi, a prostate cancer therapeutic. March-in rights give the government the right to take a license for itself if it helped to fund the product owner’s research.
The drug was being tested in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc and Astellas Pharma Inc., in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.
IC continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade.
The new office is aimed at closing up crucial gaps in monitoring for potential threats, according to a Bloomberg report, which cited a person who attended a town hall held yesterday at the agency’s headquarters in Atlanta.
Although the pandemic gave a boost to the drug discovery market, accelerated development in the market will be influenced by effective use of data and analytics.
Through ongoing collaboration, new companion diagnostic aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology.
The FDA’s Peripheral and Central Nervous System Drugs advisory committee will discuss the merits of Biogen and Ionis’s ALS candidate tofersen on March 22nd.
Company president and CEO Bernard Coulie, M.D., Ph.D. called the data “unprecedented in IPF clinical drug development”.
J&J’s large pharmaceuticals business is its major profit engine and the company is betting on that and its devices unit as the healthcare conglomerate prepares to spin off its consumer health business by the end of this year.